Home / BusinessBusinessFinancial TimesBusinessFinancial Times·Sep 20, 2026·1 min readNovo investors call for dealmaking and new drugsOzempic maker is under pressure to diversify as it prepares to face shareholders on MondayView original source — Financial Times ↗ShareCopy linkShare on XShare on FacebookRelated storiesBusinessMarketWatchBusinessSep 14, 2026 · 1 minNovo drops ‘Nordisk’ in corporate refresh to take on Lilly in the weight-loss warsMarketWatchBusinessCNBCBusinessSep 14, 2026 · 1 minNovo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market shareCNBCHealthSouth China Morning PostHealthSep 14, 2026 · 1 minOzempic-maker Novo Nordisk slims down to ‘Novo’South China Morning PostTechnologyThe Next WebTechnologySep 16, 2026 · 1 minNovo will test Anthropic’s Claude Science to speed up drug discoveryThe Next Web
BusinessMarketWatchBusinessSep 14, 2026 · 1 minNovo drops ‘Nordisk’ in corporate refresh to take on Lilly in the weight-loss warsMarketWatch
BusinessCNBCBusinessSep 14, 2026 · 1 minNovo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market shareCNBC
HealthSouth China Morning PostHealthSep 14, 2026 · 1 minOzempic-maker Novo Nordisk slims down to ‘Novo’South China Morning Post
TechnologyThe Next WebTechnologySep 16, 2026 · 1 minNovo will test Anthropic’s Claude Science to speed up drug discoveryThe Next Web